Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial

Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial
Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based chemotherapy plus Avastin, interim results from a Phase 2 trial show. These findings are in the presentation, “Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab,” for the May 14 webinar as part of the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer. The meeting, set for March in Toronto, was canceled due to the COVID-19 pandemic. Avastin, developed by Genentech (part of the Roche Group), belongs to a class of medications known as anti-angiogenic therapies. It works by stopping tumors from making their own blood vessels, thereby limiting cancer growth. Zejula is an oral PARP inhibitor marketed by Tesaro, a subsidiary of GlaxoSmithKline. It works by blocking the activity of PARP enzymes, which are involved in DNA repair. By inhibiting these enzymes, Zejula prevents cancer cells from repairing their DNA, eventually leading to their death. The safety and efficacy of both medications when used as maintenance therapy for ovarian cancer is being investigated in an open-label, Tesaro-sponsored Phase 2 trial (NCT03326193) called OVARIO. It enrolled 105 women (median age of 60) with advanced ovarian cancer who had responded to first-line treatment with platinum-based chemotherapy in combination with Avastin. During the trial, participants received Avastin at a dose of 15 mg/kg, administered intravenously (into the bloodstream) every three weeks for up to 15 months, including time on the first-line chemotherapy. Ze
Subscribe or to access all post and page content.